{
    "nct_id": "NCT05891938",
    "title": "Effects of Hydrogen Gas Inhalation on Community-Dwelling Adults of Various Ages: A Single-Arm, Open-Label, Prospective Clinical Trial",
    "status": "COMPLETED",
    "last_update_time": "2023-06-06",
    "description_brief": "Herein, investigated the effects of 4 weeks of H2 gas inhalation on community-dwelling adults of various ages.",
    "description_detailed": "Molecular hydrogen (H2) is a versatile therapeutic agent. H2 gas inhalation is reportedly safe and has a positive impact on a range of illnesses, including Alzheimer's disease (AD). Herein, investigated the effects of 4 weeks of H2 gas inhalation on community-dwelling adults of various ages. Fifty-four participants including those dropped out (5%) were screened and enrolled. The selected participants were treated as a single group without randomization. Evaluated the association between total and differential white blood cell (WBC) counts and AD risk at individual levels after 4 weeks of H2 gas inhalation treatment. Furthermore, evaluation of dementia-related biomarkers such as beta-site APP cleaving enzyme 1 (BACE-1), amyloid beta (A\u03b2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor A (VEGF-A), T-tau, monocyte chemotactic protein-1 (MCP-1), and inflammatory cytokines (interleukin-6).",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "PREVENTION",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Hydrogen gas (molecular hydrogen, H2) inhalation"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The intervention is inhaled molecular hydrogen (H2), a small diatomic molecule administered as a therapeutic gas. The Antioxidants (2023) single-arm trial reports that 4 weeks of H2 inhalation decreased oxidative stress markers and reduced Alzheimer\u2019s-related biomarkers (BACE\u20111, A\u03b21\u201140/1\u201142, t\u2011tau, p\u2011tau) and inflammatory markers, suggesting an effect on disease-related pathology rather than only transient symptomatic relief. \ue200cite\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 Drug/intervention: molecular hydrogen (H2) gas inhalation; Study design: single\u2011arm, open\u2011label, 4\u2011week inhalation in community\u2011dwelling adults (no placebo arm). The PubMed entry and the PMC full text describe the same trial and outcomes. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect: Classification rationale and caveats \u2014 I classified this as 'disease\u2011targeted small molecule' because H2 is a small molecule (H2 gas) and the trial documents reductions in AD\u2011related biomarkers (amyloid, tau, BACE\u20111), consistent with a putative disease\u2011modifying action rather than solely symptomatic cognitive enhancement. However, this is somewhat ambiguous: H2\u2019s proposed mechanism is broad antioxidant/anti\u2011inflammatory/neuroprotective (not a targeted enzyme inhibitor like a BACE inhibitor), and many studies are small/open\u2011label; some consider H2 a general neuroprotective therapy rather than a pathology\u2011specific agent. An open\u2011label AD pilot also reports potential longer\u2011term AD benefits after H2 inhalation, supporting disease\u2011modifying claims but still limited by study design. Given the molecule type (non\u2011biologic, molecular H2) and the reported effects on disease biomarkers, the closest fit among the provided categories is 'disease-targeted small molecule'. \ue200cite\ue202turn0search5\ue202turn0search1\ue201",
        "Web search results used (for transparency): 1) 'Effects of Hydrogen Gas Inhalation on Community\u2011Dwelling Adults of Various Ages: A Single\u2011Arm, Open\u2011Label, Prospective Clinical Trial' \u2014 full text (Antioxidants 2023 / PMC). \ue200cite\ue202turn0search1\ue201 2) PubMed entry for the same Antioxidants 2023 trial. \ue200cite\ue202turn0search0\ue201 3) 'Therapeutic Inhalation of Hydrogen Gas for Alzheimer's Disease Patients and Subsequent Long\u2011Term Follow\u2011Up as a Disease\u2011Modifying Treatment: An Open Label Pilot Study' \u2014 PubMed (pilot AD study supporting potential disease\u2011modifying effects). \ue200cite\ue202turn0search5\ue201"
    ],
    "agent_type": "G) Oxidative Stress",
    "explanation_agent": [
        "Reason: The intervention is inhaled molecular hydrogen (H2), a small diatomic gas whose reported primary mechanism in the cited trials and reviews is antioxidant activity (reduction of reactive oxygen/nitrogen species and oxidative-stress markers), with secondary anti-inflammatory and neuroprotective effects \u2014 i.e., it is aimed at reducing oxidative stress that contributes to AD pathology. \ue200cite\ue202turn1search1\ue202turn0search1\ue201",
        "Act: Extracted details and assignment \u2014 Drug/intervention: molecular hydrogen (H2) gas inhalation; Study findings: decreases in oxidative stress markers and reductions in AD-related blood biomarkers (BACE\u20111, A\u03b21\u201140/1\u201142, t\u2011tau/p\u2011tau) and inflammatory markers after H2 inhalation. Because the dominant, putative mechanism cited is antioxidant (oxidative\u2011stress reduction), the most specific CADRO category match is G) Oxidative Stress. \ue200cite\ue202turn1search1\ue201",
        "Reflect: Confirmation and caveats \u2014 H2 also shows anti\u2011inflammatory and general neuroprotective effects (which could point to F) Inflammation or M) Synaptic Plasticity/Neuroprotection), and some studies are small/open\u2011label; however, primary mechanistic claims and the biomarker changes reported emphasize reduction of oxidative damage and activation of antioxidant pathways (e.g., Nrf2), supporting classification as G) Oxidative Stress. If future data show a clearly dominant alternative mechanism, reclassification (or multi\u2011target R) could be considered. \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Web search results used (for transparency): Antioxidants 2023 single\u2011arm trial (full text, molecular hydrogen inhalation showing decreased oxidative stress and AD biomarkers). \ue200cite\ue202turn1search1\ue201; PubMed/Pharmaceuticals open\u2011label AD pilot (H2 inhalation showing clinical and imaging changes consistent with possible disease\u2011modifying effects). \ue200cite\ue202turn0search0\ue201; MDPI review/discussion of H2 mechanisms including antioxidant, Nrf2 activation, BBB penetration and anti\u2011cell\u2011death effects. \ue200cite\ue202turn0search1\ue201"
    ]
}